Advertisement

U.S. markets open in 31 minutes

S&P Futures
4,251.25
-29.75(-0.69%)
Dow Futures
33,496.00
-222.00(-0.66%)
Nasdaq Futures
13,511.50
-66.25(-0.49%)
Russell 2000 Futures
1,998.30
-18.60(-0.92%)
Crude Oil
87.11
-4.98(-5.41%)
Gold
1,791.80
-23.70(-1.31%)

Advertisement

Monte Rosa Therapeutics, Inc. (GLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

10.03

+0.87

(+9.50%)

At close: 04:00PM EDT

10.07

+0.04

(+0.40%)

Pre-Market:

08:51AM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	9.16
Open	9.18
Bid	6.00 x 800
Ask	10.79 x 3200
Day's Range	9.18 - 10.65
52 Week Range	6.05 - 45.56
Volume	383,061
Avg. Volume	203,491

Market Cap	468.54M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-2.36
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	24.43

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GLUE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Monte Rosa Therapeutics, Inc.
Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Rating
Fair Value
Economic Moat
11 days agoMorningstar

All

GlobeNewswire
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022 – BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business hig
- Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
  Business Wire
- GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
  GlobeNewswire
American City Business Journals
Upcoming 220K-square-foot South End lab project almost fully leased
The BPDA cleared the way last summer for a roughly 220,000-square-foot lab and research-and-development site in a neighborhood that is seeing an influx of life sciences space.
GlobeNewswire
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year – – Initiated Research with École Polytechnique Fédérale de Lausanne (EPFL); Collaboration to Broaden Monte Rosa’s AI Capabilities – BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company dev